HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
Figure 4
Protein expression changes after NB4, HL60, and APL patient’s cell treatment with epigenetic agents in combination with conventional treatment. Cell samples were treated with 1 μM Retinoic acid (RA), 2 nM or 8 nM Idarubicin (IDA2 or IDA8), 0.5 μM 3-Deazaneplanocin A (D), and 0.2 μM Belinostat (B) in different combinations for 6 and 72 hours; C: untreated cells. (a) Protein level changes were assessed by immunoblot analysis. Intensity of protein bands was measured using ImageJ software and normalized to the GAPDH loading control; results are presented as changes in comparison to untreated cells. (b) Graphical visualization of relative band intensity of detected protein levels as measured using ImageJ software and normalized to the GAPDH loading control; results are mean ± S.D. (n=2).